drug
as of 2026-07-01Cannabidiol
Cannabidiol CRCannabidiol (CBD)Cannabidiol oral solutionCannabidiol as add-onCBD 100 mg/mL Oral Solutioncannabidiol
MeSH D002185
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Central Institute of Mental Health, Mannheim
18 trials in the graph
Synthesized from structured facts only — each point cited above.
Mechanism & identity
Modality
small molecule
Indications
Investigational (via trials)
Trials
18
Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis
NCT03883360Phase 2Withdrawn
Stratification and Treatment in Early Psychosis Study - PROMOTE
NCT07434973Phase 3Not Yet Recruiting
Stratification and Treatment in Early Psychosis Study -ASSIST
NCT07326124Phase 3Not Yet Recruiting
Stratification and Treatment in Early Psychosis Study - ENHANCE
NCT06778564Phase 3Not Yet Recruiting
Enhancing Recovery in Early Schizophrenia
NCT02926859Phase 2Active Not Recruiting
Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis
NCT04411225Phase 3Recruiting
Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use
NCT04105231Phase 2Active Not Recruiting
Evaluation Study of New Compounds With Potential Use in Schizophrenia
NCT00916201Phase 1Withdrawn
A Four-week Clinical Trial Investigating Efficacy and Safety of Cannabidiol As a Treatment for Acutely Ill Schizophrenic Patients
NCT02088060Phase 2Terminated
A Study of Tolerability and Efficacy of Cannabidiol on Motor Symptoms in Parkinson's Disease
NCT03582137Phase 2Completed
Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia
NCT02932605—Completed
Cannabidiol Treatment in Patients With Early Psychosis
NCT02504151Phase 2Completed
A Study of Tolerability and Efficacy of Cannabidiol on Tremor in Parkinson's Disease
NCT02818777Phase 2Completed
Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study
NCT02051387Phase 1Completed
The Effects of Cannabidiol and ∆-9-THC in Humans
NCT01180374Early Phase 1Completed
Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia
NCT00588731Phase 2Completed
Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis
NCT00628290Phase 2Completed
KOLs & investigators
10
Philip McGuire, MD, PhD, ProfKOL score 11
F. Markus Leweke, MDKOL score 9
Lone Baandrup, MD, PhDKOL score 7
Mohini Ranganathan, M.D.KOL score 5
Kristin S Cadenhead, MDKOL score 5
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
trial
trial
indication
KOL
Philip McGuire, MD, PhD, Prof
personKOL score 11
F. Markus Leweke, MD
personKOL score 9
Lone Baandrup, MD, PhD
personKOL score 7
Mohini Ranganathan, M.D.
personKOL score 5